BCAX insider plans to sell 22,000 shares on Nasdaq for $405,900

Rhea-AI Filing Summary

Bicara Therapeutics (BCAX) filed a Form 144 notice disclosing a proposed sale of 22,000 common shares, acquired the same day by exercising stock options. The broker listed is UBS Financial Services and the shares are to be sold on Nasdaq with an approximate aggregate market value of $405,900. The filing reports 54,562,841 shares outstanding and indicates the proposed sale date as 10/09/2025. No securities were reported sold in the prior three months. The filer attests they are not aware of undisclosed material adverse information and notes exercise payment was made in cash.

Positive

• Exercise and sale are disclosed, showing procedural transparency under Rule 144
• No prior sales in the past three months, simplifying aggregation calculations
• Cash payment for the option exercise indicates completed consideration at acquisition

Negative

• Insider sale planned of 22,000 shares (aggregate $405,900), which could modestly increase selling pressure
• No additional context provided about the insider's reason for sale beyond the standard attestation

Insights

Insider Transactions Analyst

Insider plans to liquidate option exercise proceeds via market sale.

The notice shows an insider exercised options and plans to sell 22,000 shares on 10/09/2025 through UBS, producing an aggregate market value of $405,900. This is a routine issuer-related liquidity event rather than an open-market accumulation or secondary offering.

The main dependency is timing and execution: sale proceeds depend on market price at execution and the broker's routing. Because the position equals roughly 0.04% of outstanding shares (22,000 of 54,562,841), immediate market impact is likely limited; watch actual execution reports around 10/09/2025 for realized prices.

Corporate Governance Specialist

Procedure and attestation follow standard Rule 144 requirements.

The filer includes the required attestation that no undisclosed material adverse information exists and specifies cash payment for the option exercise on the acquisition date. The filing lists no prior sales in the past three months, which supports compliance with the aggregation rules under Rule 144.

Key items to monitor are any subsequent Form 4 or Form 5 filings that disclose actual sale prices or changes in beneficial ownership, typically filed after the transaction settles around 10/09/2025. Such filings will confirm execution and final compliance details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Avenue 4th Floor New York NY 10010	22000	405900.00	54562841	10/09/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/09/2025	Exercise of Stock Options	Issuer			22000	10/09/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What transaction does Bicara Therapeutics (BCAX) disclose on Form 144?

The filing discloses a proposed sale of 22,000 common shares acquired by exercise of stock options on 10/09/2025, to be sold on Nasdaq via UBS.

How much are the proposed Bicara (BCAX) shares worth in the Form 144?

The aggregate market value reported is $405,900 for the 22,000 shares to be sold.

How many Bicara (BCAX) shares are outstanding according to the filing?

The filing lists 54,562,841 shares outstanding.

Was payment made for the Bicara (BCAX) option exercise?

Yes. The filing shows the option exercise was paid in cash on 10/09/2025.

Does the filing report other sales by the same person in the prior three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.